SL 251131

Drug Profile

SL 251131

Latest Information Update: 30 Jun 2003

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Class
  • Mechanism of Action Monoamine oxidase A inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Major depressive disorder; Parkinson's disease

Most Recent Events

  • 28 Feb 2003 Discontinued - Phase-I for Depression in France (unspecified route)
  • 28 Feb 2003 Discontinued - Phase-I for Parkinson's disease in France (unspecified route)
  • 08 Mar 2002 Phase-I clinical trials in Parkinson's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top